Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8064364 | 0.90 | SMN1; SMN2 (0.47) | KMT2AGAACYP1A2FAAHSMN1; SMN2 | |
| SCHEMBL3995471 | 0.88 | LMNA (0.44) | KMT2AGAACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20419549 | 0.86 | AURKA (0.40) | KMT2AGAASMN1; SMN2POLBKDM4E | |
| SCHEMBL24275916 | 0.84 | FAAH (0.43) | KMT2AGAACYP1A2FAAHCYP2C19 | |
| SCHEMBL3646146 | 0.83 | MARS1 (0.46) | GAAPOLBMAPTKDM4EALDH1A1 | |
| SCHEMBL7703521 | 0.83 | LMNA (0.52) | KMT2AGAACYP1A2FAAHCYP2C9 | |
| SCHEMBL1234127 | 0.82 | AURKA (0.52) | KMT2AGAACYP1A2FAAHPOLB | |
| SCHEMBL8076665 | 0.81 | FAAH (0.40) | KMT2AGAACYP1A2FAAHSMN1; SMN2 | |
| SCHEMBL3999420 | 0.81 | KMT2A (0.38) | KMT2AGAACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5560879 | 0.81 | CYP1A2 (0.46) | KMT2AGAACYP1A2FAAHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022053010-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-03-17 | — | — | WO | disclosed |
| EP-2185525-B1 | PYRAZOLE 3,5 CARBOXYLATE DERIVATIVES PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2016-12-14 | — | — | EP | disclosed |
| US-9102628-B2 | Derivatives of pyrazole 3,5-carboxylates, their preparation and their application in therapeutics | SANOFI (FR) | 2015-08-11 | — | — | US | disclosed |
| US-9102628-B2 | Derivatives of pyrazole 3,5-carboxylates, their preparation and their application in therapeutics | SANOFI (FR) | 2015-08-11 | — | — | US | disclosed |
| US-9102628-B2 | Derivatives of pyrazole 3,5-carboxylates, their preparation and their application in therapeutics | SANOFI (FR) | 2015-08-11 | — | — | US | disclosed |
| US-20100160377-A1 | DERIVATIVES OF PYRAZOLE 3,5-CARBOXYLATES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | US | disclosed |
| US-20100160377-A1 | DERIVATIVES OF PYRAZOLE 3,5-CARBOXYLATES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | US | disclosed |
| US-20100160377-A1 | DERIVATIVES OF PYRAZOLE 3,5-CARBOXYLATES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | US | disclosed |
| WO-2009027601-A2 | PYRAZOLE 3,5 CARBOXYLATE DERIVATIVES PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160377-A1 | DERIVATIVES OF PYRAZOLE 3,5-CARBOXYLATES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | CYP3A5, ADH5, AVPR2 | KMT2A 4426/4885GAA 2371/4885CYP1A2 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.